Health Canada Approves Second Martek DHA For Food Uses

Health Canada Approves Second Martek DHA For Food Uses Company announces that now all of its DHA omega-3 products have been approved by Health Canada for use as food ingredients in most foods.
Home Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P. Natrol Appoints Vincent Andrich VP Sales for Prolab Division Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results Body Shop Reports 24.8 Mil Euro Sales Revenues Supplement Group Targets Consumer Education Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO drugstore.com Expects to Reach Profitability Target in 2003 Human Genome Project Leads to Innovative Healthcare NPIcenter’s Career Center targets nutraceutical Industry Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders Editorial: An Exercise in Synergy NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway Natural Health Trends Corp. Launches Lexxus Taiwan New TrimFit® Bars Redefine Energy Bar Category New TrimFit® Bars Redefine Energy Bar Category Probiata® Offers Safe, Natural and Effective Alternative Alive & Well with Michelle Harris Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com Consumers Search for Healthy Cleaning Products That Work Nordic Naturals: Omega 3 Fatty Acids Cyanotech Names Bob Capelli as Director of Sales Nutraceutical Clinical Laboratories International, Inc., Secures $2 Million in Funding KAVA ADVISORY: Health Canada is advising consumers not to use any products containing kava GRAS Status Affirmed for Lipogen Phosphatidylserine Company announces that FDA has no questions regarding the GRAS notification for its Lipogen PS (phosphatidylserine) patented product line. GRAS Status Affirmed for Lipogen Phosphatidylserine Company announces that FDA has no questions regarding the GRAS notification for its Lipogen PS (phosphatidylserine) patented product line. GRAS Status Affirmed for Lipogen Phosphatidylserine Company announces that FDA has no questions regarding the GRAS notification for its Lipogen PS (phosphatidylserine) patented product line. NSF International Awards First GMP for Sport(TM) Registration to Century Foods International NSF International announced that Century Foods International is the first manufacturing facility to receive Good Manufacturing Practices (GMP) for Sport™ registration, a new program that builds on NSF’s GMP Registration Program. NSF International Awards First GMP for Sport(TM) Registration to Century Foods International NSF International announced that Century Foods International is the first manufacturing facility to receive Good Manufacturing Practices (GMP) for Sport™ registration, a new program that builds on NSF’s GMP Registration Program. NSF International Awards First GMP for Sport(TM) Registration to Century Foods International NSF International announced that Century Foods International is the first manufacturing facility to receive Good Manufacturing Practices (GMP) for Sport™ registration, a new program that builds on NSF’s GMP Registration Program. NSF International Awards First GMP for Sport(TM) Registration to Century Foods International NSF International announced that Century Foods International is the first manufacturing facility to receive Good Manufacturing Practices (GMP) for Sport™ registration, a new program that builds on NSF’s GMP Registration Program. NSF International Awards First GMP for Sport(TM) Registration to Century Foods International NSF International announced that Century Foods International is the first manufacturing facility to receive Good Manufacturing Practices (GMP) for Sport™ registration, a new program that builds on NSF’s GMP Registration Program. NSF International Awards First GMP for Sport(TM) Registration to Century Foods International NSF International announced that Century Foods International is the first manufacturing facility to receive Good Manufacturing Practices (GMP) for Sport™ registration, a new program that builds on NSF’s GMP Registration Program. FDA Asks U.S. Marshals to Seize Dietary Supplements Products Being Promoted With Drug Claims At the request of the U.S. Food and Drug Administration (FDA), on September 5, 2006, U.S. Marshals seized quantities of Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support capsules distributed by Advantage Nutraceuticals L.L.C. of Fort Walton Beach, Florida, valued at approximately $55,000.00. The products are alleged to be in violation of the new drug and misbranding provisions of the Federal Food, Drug and Cosmetic Act. FDA Asks U.S. Marshals to Seize Dietary Supplements Products Being Promoted With Drug Claims At the request of the U.S. Food and Drug Administration (FDA), on September 5, 2006, U.S. Marshals seized quantities of Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support capsules distributed by Advantage Nutraceuticals L.L.C. of Fort Walton Beach, Florida, valued at approximately $55,000.00. The products are alleged to be in violation of the new drug and misbranding provisions of the Federal Food, Drug and Cosmetic Act. FDA Asks U.S. Marshals to Seize Dietary Supplements Products Being Promoted With Drug Claims At the request of the U.S. Food and Drug Administration (FDA), on September 5, 2006, U.S. Marshals seized quantities of Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support capsules distributed by Advantage Nutraceuticals L.L.C. of Fort Walton Beach, Florida, valued at approximately $55,000.00. The products are alleged to be in violation of the new drug and misbranding provisions of the Federal Food, Drug and Cosmetic Act. FDA Asks U.S. Marshals to Seize Dietary Supplements Products Being Promoted With Drug Claims At the request of the U.S. Food and Drug Administration (FDA), on September 5, 2006, U.S. Marshals seized quantities of Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support capsules distributed by Advantage Nutraceuticals L.L.C. of Fort Walton Beach, Florida, valued at approximately $55,000.00. The products are alleged to be in violation of the new drug and misbranding provisions of the Federal Food, Drug and Cosmetic Act. FDA Asks U.S. Marshals to Seize Dietary Supplements Products Being Promoted With Drug Claims At the request of the U.S. Food and Drug Administration (FDA), on September 5, 2006, U.S. Marshals seized quantities of Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support capsules distributed by Advantage Nutraceuticals L.L.C. of Fort Walton Beach, Florida, valued at approximately $55,000.00. The products are alleged to be in violation of the new drug and misbranding provisions of the Federal Food, Drug and Cosmetic Act. DEA: Hi-Tech Pharmaceuticals & 11 Individuals Indicted for "Generic" Pill Fraud Scheme Hi-Tech Pharmaceuticals & 11 Individuals have been indicted by a federal grand jury on multiple felony charges relating to a scheme to sell adulterated and unapproved new drugs over the internet. DEA: Hi-Tech Pharmaceuticals & 11 Individuals Indicted for "Generic" Pill Fraud Scheme Hi-Tech Pharmaceuticals & 11 Individuals have been indicted by a federal grand jury on multiple felony charges relating to a scheme to sell adulterated and unapproved new drugs over the internet. Navamedic’s product Glucomed®/Flexove(TM) approved in EU by CHMP Navamedic has received notice that its glucosamine HCl product Glucomed®/Flexove(TM) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP). The approval will be valid for all 25 EU/EEA countries in Navamedic’s application. Navamedic’s product Glucomed®/Flexove(TM) approved in EU by CHMP Navamedic has received notice that its glucosamine HCl product Glucomed®/Flexove(TM) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP). The approval will be valid for all 25 EU/EEA countries in Navamedic’s application. Navamedic’s product Glucomed®/Flexove(TM) approved in EU by CHMP Navamedic has received notice that its glucosamine HCl product Glucomed®/Flexove(TM) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP). The approval will be valid for all 25 EU/EEA countries in Navamedic’s application. Navamedic’s product Glucomed®/Flexove(TM) approved in EU by CHMP Navamedic has received notice that its glucosamine HCl product Glucomed®/Flexove(TM) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP). The approval will be valid for all 25 EU/EEA countries in Navamedic’s application. Navamedic’s product Glucomed®/Flexove(TM) approved in EU by CHMP Navamedic has received notice that its glucosamine HCl product Glucomed®/Flexove(TM) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP). The approval will be valid for all 25 EU/EEA countries in Navamedic’s application. Ontario Government Closer to Regulating Traditional Chinese Medicine Ontario has moved closer to regulating traditional Chinese medicine (TCM) and acupuncture as the proposed legislation moved to second reading. Ontario Government Closer to Regulating Traditional Chinese Medicine Ontario has moved closer to regulating traditional Chinese medicine (TCM) and acupuncture as the proposed legislation moved to second reading. Ontario Government Closer to Regulating Traditional Chinese Medicine Ontario has moved closer to regulating traditional Chinese medicine (TCM) and acupuncture as the proposed legislation moved to second reading. FDA Authorizes Qualified Health Claim for Canola Oil The U.S. Food and Drug Administration has announced that canola oil is now eligible to bear a qualified health claim on its ability to reduce the risk of coronary heart disease (CHD) due to its unsaturated fat content. The claim, which canola oil bottlers and makers of eligible products* may use on labels, states: Limited and not conclusive scientific evidence suggests that eating about 1 1/2 tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of canola oil. FDA Authorizes Qualified Health Claim for Canola Oil The U.S. Food and Drug Administration has announced that canola oil is now eligible to bear a qualified health claim on its ability to reduce the risk of coronary heart disease (CHD) due to its unsaturated fat content. The claim, which canola oil bottlers and makers of eligible products* may use on labels, states: Limited and not conclusive scientific evidence suggests that eating about 1 1/2 tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of canola oil. FDA Authorizes Qualified Health Claim for Canola Oil The U.S. Food and Drug Administration has announced that canola oil is now eligible to bear a qualified health claim on its ability to reduce the risk of coronary heart disease (CHD) due to its unsaturated fat content. The claim, which canola oil bottlers and makers of eligible products* may use on labels, states: Limited and not conclusive scientific evidence suggests that eating about 1 1/2 tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of canola oil. FDA Authorizes Qualified Health Claim for Canola Oil The U.S. Food and Drug Administration has announced that canola oil is now eligible to bear a qualified health claim on its ability to reduce the risk of coronary heart disease (CHD) due to its unsaturated fat content. The claim, which canola oil bottlers and makers of eligible products* may use on labels, states: Limited and not conclusive scientific evidence suggests that eating about 1 1/2 tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of canola oil. FDA Authorizes Qualified Health Claim for Canola Oil The U.S. Food and Drug Administration has announced that canola oil is now eligible to bear a qualified health claim on its ability to reduce the risk of coronary heart disease (CHD) due to its unsaturated fat content. The claim, which canola oil bottlers and makers of eligible products* may use on labels, states: Limited and not conclusive scientific evidence suggests that eating about 1 1/2 tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of canola oil. FDA Authorizes Qualified Health Claim for Canola Oil The U.S. Food and Drug Administration has announced that canola oil is now eligible to bear a qualified health claim on its ability to reduce the risk of coronary heart disease (CHD) due to its unsaturated fat content. The claim, which canola oil bottlers and makers of eligible products* may use on labels, states: Limited and not conclusive scientific evidence suggests that eating about 1 1/2 tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of canola oil. Allimax Nutraceuticals US starts clinical trial for treating Lyme disease Allimax Nutraceuticals US, in conjunction with the Health Healing and Hope Foundation, have started their Lyme disease double blind clinical study being conducted in Texas by Dr.’s Joan Vandergriff ND, Hamid Moayad DO, William Keller Ph.D., Hugo Rodier M.D. Allimax Nutraceuticals US starts clinical trial for treating Lyme disease Allimax Nutraceuticals US, in conjunction with the Health Healing and Hope Foundation, have started their Lyme disease double blind clinical study being conducted in Texas by Dr.’s Joan Vandergriff ND, Hamid Moayad DO, William Keller Ph.D., Hugo Rodier M.D. Health Canada Issues 'Approach to the Refusal of Product license Applications' Health Canada has issued a notice regarding its approach to the refusal of Product License Applications. The approach is posted at http://www.hc-sc.gc.ca/dhp-mps/prodnatur/bulletins/pl-ref-lp_e.html. Health Canada Issues 'Approach to the Refusal of Product license Applications' Health Canada has issued a notice regarding its approach to the refusal of Product License Applications. The approach is posted at http://www.hc-sc.gc.ca/dhp-mps/prodnatur/bulletins/pl-ref-lp_e.html. Health Canada Issues 'Approach to the Refusal of Product license Applications' Health Canada has issued a notice regarding its approach to the refusal of Product License Applications. The approach is posted at http://www.hc-sc.gc.ca/dhp-mps/prodnatur/bulletins/pl-ref-lp_e.html. Indian Food Safety and Standards Bill 2005 signed into law. GCI Nutrients-India reports that the Indian Food Safety and Standards Bill 2005 was recently signed into law by the President of India. Indian Food Safety and Standards Bill 2005 signed into law. GCI Nutrients-India reports that the Indian Food Safety and Standards Bill 2005 was recently signed into law by the President of India. NHPD October 2006 Monthly Communiqué Available The NHPD Monthly Communiqué, October 2006 (Vol. 2, Issue 2), is now available online. NHPD October 2006 Monthly Communiqué Available The NHPD Monthly Communiqué, October 2006 (Vol. 2, Issue 2), is now available online. NHPD October 2006 Monthly Communiqué Available The NHPD Monthly Communiqué, October 2006 (Vol. 2, Issue 2), is now available online. Talks Ongoing: Trans-Tasman regulatory scheme A second phase of consultation on the proposed trans-Tasman regulatory scheme for therapeutic products is now underway and feedback is being invited. Talks Ongoing: Trans-Tasman regulatory scheme A second phase of consultation on the proposed trans-Tasman regulatory scheme for therapeutic products is now underway and feedback is being invited. United Natural Products Alliance (UNPA) Statement On The Status of Federal Dietary Supplement Serious Adverse Event Reporting Legislation UNPA will continue to work aggressively for passage of the Non-Prescription Drug and Dietary Supplement Consumer Protection Act (S.3546/H.R.6168) when the Congress reconvenes for a brief “lame duck” session the week after the November elections. United Natural Products Alliance (UNPA) Statement On The Status of Federal Dietary Supplement Serious Adverse Event Reporting Legislation UNPA will continue to work aggressively for passage of the Non-Prescription Drug and Dietary Supplement Consumer Protection Act (S.3546/H.R.6168) when the Congress reconvenes for a brief “lame duck” session the week after the November elections. United Natural Products Alliance (UNPA) Statement On The Status of Federal Dietary Supplement Serious Adverse Event Reporting Legislation UNPA will continue to work aggressively for passage of the Non-Prescription Drug and Dietary Supplement Consumer Protection Act (S.3546/H.R.6168) when the Congress reconvenes for a brief “lame duck” session the week after the November elections. United Natural Products Alliance (UNPA) Statement On The Status of Federal Dietary Supplement Serious Adverse Event Reporting Legislation UNPA will continue to work aggressively for passage of the Non-Prescription Drug and Dietary Supplement Consumer Protection Act (S.3546/H.R.6168) when the Congress reconvenes for a brief “lame duck” session the week after the November elections. Advisory - Health Canada advises consumers not to use four unauthorized natural health products that claim to treat serious diseases Health Canada is advising consumers not to use four unauthorized natural health products, Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support capsules, that are promoted to treat serious health conditions such as cancer, arthritis and heart disease because such unapproved health claims are in violation of the Food and Drugs Act. Advisory - Health Canada advises consumers not to use four unauthorized natural health products that claim to treat serious diseases Health Canada is advising consumers not to use four unauthorized natural health products, Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support capsules, that are promoted to treat serious health conditions such as cancer, arthritis and heart disease because such unapproved health claims are in violation of the Food and Drugs Act. Advisory - Health Canada advises consumers not to use four unauthorized natural health products that claim to treat serious diseases Health Canada is advising consumers not to use four unauthorized natural health products, Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support capsules, that are promoted to treat serious health conditions such as cancer, arthritis and heart disease because such unapproved health claims are in violation of the Food and Drugs Act. Plant sterols and formulated beverages now approved New standards allow Australians and New Zealanders to have access to a range of foods enriched with plant sterols, and allow manufacturers to make formulated beverages in Australia, not just New Zealand. Plant sterols and formulated beverages now approved New standards allow Australians and New Zealanders to have access to a range of foods enriched with plant sterols, and allow manufacturers to make formulated beverages in Australia, not just New Zealand. SelenoExcell® Receives Independent GRAS Evaluation Company has received independent GRAS designation for its flagship product SelenoExcell® High Selenium Yeast use in several food categories. SelenoExcell® Receives Independent GRAS Evaluation Company has received independent GRAS designation for its flagship product SelenoExcell® High Selenium Yeast use in several food categories. SelenoExcell® Receives Independent GRAS Evaluation Company has received independent GRAS designation for its flagship product SelenoExcell® High Selenium Yeast use in several food categories. SelenoExcell® Receives Independent GRAS Evaluation Company has received independent GRAS designation for its flagship product SelenoExcell® High Selenium Yeast use in several food categories. SelenoExcell® Receives Independent GRAS Evaluation Company has received independent GRAS designation for its flagship product SelenoExcell® High Selenium Yeast use in several food categories. SelenoExcell® Receives Independent GRAS Evaluation Company has received independent GRAS designation for its flagship product SelenoExcell® High Selenium Yeast use in several food categories. FDA Approves Special Green Tea Extract as a New Topical Drug for Genital Warts Last week the U.S. Food and Drug Administration (FDA) approved a special extract of green tea as a prescription drug for the topical (external) treatment of genital warts caused by the human papilloma virus (HPV). The new drug, called Veregen™ (Polyphenon® E) Ointment is the first prescription botanical (herbal) drug approved by FDA under the “new” drug amendments of 1962 that required drugs to be proven both safe and effective prior to being marketed in the U.S. FDA Approves Special Green Tea Extract as a New Topical Drug for Genital Warts Last week the U.S. Food and Drug Administration (FDA) approved a special extract of green tea as a prescription drug for the topical (external) treatment of genital warts caused by the human papilloma virus (HPV). The new drug, called Veregen™ (Polyphenon® E) Ointment is the first prescription botanical (herbal) drug approved by FDA under the “new” drug amendments of 1962 that required drugs to be proven both safe and effective prior to being marketed in the U.S. FDA Approves Special Green Tea Extract as a New Topical Drug for Genital Warts Last week the U.S. Food and Drug Administration (FDA) approved a special extract of green tea as a prescription drug for the topical (external) treatment of genital warts caused by the human papilloma virus (HPV). The new drug, called Veregen™ (Polyphenon® E) Ointment is the first prescription botanical (herbal) drug approved by FDA under the “new” drug amendments of 1962 that required drugs to be proven both safe and effective prior to being marketed in the U.S. FDA Approves Special Green Tea Extract as a New Topical Drug for Genital Warts Last week the U.S. Food and Drug Administration (FDA) approved a special extract of green tea as a prescription drug for the topical (external) treatment of genital warts caused by the human papilloma virus (HPV). The new drug, called Veregen™ (Polyphenon® E) Ointment is the first prescription botanical (herbal) drug approved by FDA under the “new” drug amendments of 1962 that required drugs to be proven both safe and effective prior to being marketed in the U.S. FDA Approves Special Green Tea Extract as a New Topical Drug for Genital Warts Last week the U.S. Food and Drug Administration (FDA) approved a special extract of green tea as a prescription drug for the topical (external) treatment of genital warts caused by the human papilloma virus (HPV). The new drug, called Veregen™ (Polyphenon® E) Ointment is the first prescription botanical (herbal) drug approved by FDA under the “new” drug amendments of 1962 that required drugs to be proven both safe and effective prior to being marketed in the U.S. FDA Approves Special Green Tea Extract as a New Topical Drug for Genital Warts Last week the U.S. Food and Drug Administration (FDA) approved a special extract of green tea as a prescription drug for the topical (external) treatment of genital warts caused by the human papilloma virus (HPV). The new drug, called Veregen™ (Polyphenon® E) Ointment is the first prescription botanical (herbal) drug approved by FDA under the “new” drug amendments of 1962 that required drugs to be proven both safe and effective prior to being marketed in the U.S. FDA Approves Special Green Tea Extract as a New Topical Drug for Genital Warts Last week the U.S. Food and Drug Administration (FDA) approved a special extract of green tea as a prescription drug for the topical (external) treatment of genital warts caused by the human papilloma virus (HPV). The new drug, called Veregen™ (Polyphenon® E) Ointment is the first prescription botanical (herbal) drug approved by FDA under the “new” drug amendments of 1962 that required drugs to be proven both safe and effective prior to being marketed in the U.S. McGuinty Government Regulates Traditional Chinese Medicine Legislation in the province of Ontario regulating the practice of traditional Chinese medicine (TCM) has passed third and final reading and will become law once it receives Royal Assent. McGuinty Government Regulates Traditional Chinese Medicine Legislation in the province of Ontario regulating the practice of traditional Chinese medicine (TCM) has passed third and final reading and will become law once it receives Royal Assent. McGuinty Government Regulates Traditional Chinese Medicine Legislation in the province of Ontario regulating the practice of traditional Chinese medicine (TCM) has passed third and final reading and will become law once it receives Royal Assent. Debate on EU vitamins and minerals picks up pace at EHPM/ERNA conference The quest to establish EU-wide agreement on maximum levels for vitamins and minerals took a step forward last week when more than 100 stakeholders convened in Brussels to debate the issue. Debate on EU vitamins and minerals picks up pace at EHPM/ERNA conference The quest to establish EU-wide agreement on maximum levels for vitamins and minerals took a step forward last week when more than 100 stakeholders convened in Brussels to debate the issue. Debate on EU vitamins and minerals picks up pace at EHPM/ERNA conference The quest to establish EU-wide agreement on maximum levels for vitamins and minerals took a step forward last week when more than 100 stakeholders convened in Brussels to debate the issue. Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology. Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology. Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Heart Health Alert: Niacin May Reverse Hardening of the Arteries Heart Health Alert: Niacin May Reverse Hardening of the Arteries Heart Health Alert: Niacin May Reverse Hardening of the Arteries Heart Health Alert: Niacin May Reverse Hardening of the Arteries Spotlight on Savory Side Dishes Spotlight on Savory Side Dishes Spotlight on Savory Side Dishes Another Reason to Choose Healthy Lifestyle Habits Another Reason to Choose Healthy Lifestyle Habits	Martek Biosciences Corporation (Nasdaq: MATK) announced today that now all of its DHA omega-3 products have been approved by Health Canada for use as food ingredients in most foods. The approval allows for per serving levels of not less than 8 mg and not more than 100mg of Martek's DHA. Martek's DHA omega-3 oils are marketed to consumers and appear as an ingredient on food packaging under the brand name life'sDHA(TM). "Martek will be better equipped to compete for the DHA-enriched food market in Canada with this additional approval," said Steve Dubin, Martek's CEO. "Now, more people will be able to benefit from Martek's life'sDHA(TM), a vegetarian source of DHA omega-3 that can be incorporated into many foods without affecting the taste of the finished product." Martek's life'sDHA(TM) contains the long-chain polyunsaturated fatty acid DHA (docosahexaenoic acid), the key omega-3 fatty acid for brain, eye and heart health and function. Numerous scientific studies demonstrate that people of all ages, from infants to adults, may benefit from an adequate supply of DHA omega-3 in the diet. Yet, despite its importance, natural food sources of DHA omega-3 are limited, making it difficult for many people to get enough DHA omega-3 in their diets. In June 2006, another DHA omega-3 product by Martek was also approved by Health Canada for use as a food ingredient. Martek's DHA oils have been approved for use in infant formula in Canada since 2002. Foods fortified with DHA omega-3 are a growing source of DHA omega-3 in the diets of people around the world. The recent Health Canada approval of Martek's life'sDHA(TM) for use in food products at significant levels in a variety of foods will make it easier for food companies to offer products in Canada that contain meaningful levels of DHA omega-3. Life'sDHA(TM) can be added at significant levels to most foods and beverages without impacting stability or sensory characteristics. Most other DHA omega-3 products approved at significant levels for food use in Canada are derived from fish oil. Martek's life'sDHA(TM) is unique in the market because it is derived from a sustainable and vegetarian source. Made from microalgae under tightly controlled manufacturing conditions, life'sDHA(TM) is free of oceanic contaminants that may be present in certain fish or fish oils. Microalgae are the only vegetarian source of DHA omega-3, the key omega-3 for brain and eye development and function. Martek Biosciences Corporation (Nasdaq: MATK) is a leader in the innovation and development of DHA omega-3 products that promote health and wellness through every stage of life. The Company produces life'sDHA(TM), a vegetarian source of the omega-3 fatty acid DHA (docosahexaenoic acid), for use in foods, beverages, infant formula, and supplements, and ARA (arachidonic acid), an omega-6 fatty acid, for use in infant formula. For more information on Martek Biosciences, visit http://www.martek.com. Sections of this release contain forward-looking statements concerning, among other things, expectations regarding product acceptance, customer plans, Martek's competitive position in Canada, and the economic impact to Martek of Health Canada's acceptance of Martek's life'sDHA(TM) as a food ingredient. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. For instance, Martek cannot predict with certainty what its customers' future actions will be or whether the effect of the Health Canada acceptance would impact Martek's long-term competitive position. These statements should be understood in light of the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including, but not limited to, Part II, Item 1A of the Company's Form 10-Q for the fiscal quarter ended July 31, 2006 and other filed reports on Form 10-K/A, Form 10-Q and Form 8-K.
Powered By Traffic Booster Absolute News Manager Plug-in by Xigla Software